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ABSTRACT 
 
 
Introduction 
 
HIV-Associated Nephropathy (HIVAN) is the commonest cause of proteinuria, especially in 
black HIV seropositive children.  This chronic nephropathy is a late complication of untreated 
HIV that requires earlier intervention to prevent progression of renal disease.  
Microalbuminuria is an early marker of the presence of subclinical renal disease in systemic 
diseases such as diabetes mellitus and hypertension.  This study assessed the prevalence 
and clinical significance of a single screening test for microalbuminuria in a cohort of HIV 
seropositive children without any symptoms of renal disease at Chris Hani Baragwanath 
hospital situated in Johannesburg, South Africa. 
 
 
Methods 
 
A prospective study was undertaken at Chris Hani Baragwanath hospital (a major tertiary 
facility that serves the people of Soweto and the surrounding areas of southern Gauteng).  
HIV seropositive and seronegative patients from both an inpatient and outpatient ambulatory 
setting were screened for qualitative proteinuria and microalbuminuria. Those on antiretroviral 
therapy, anti tuberculosis treatment, known chronic kidney disease, hypertension, fever, 
acute illness and urinary tract infection were excluded from the study.   
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Results 
 
180 patients were enrolled into the study, of which 110 were HIV positive and 70 HIV 
negative.  Majority of the patients were black (98%) with 100 (56%) males and 80 (44%) 
females.  Microalbuminuria was present in 27(25%) of HIV positive patients and 1 (1%) HIV 
negative patient, p=0.00003.  The mean age at presentation of microalbuminuric HIV positive 
patients was 6 ± 3.2 years.  With normal renal function and no proteinuria; microalbuminuria 
was present in 21 (19%) patients, p=0.03.  Microalbuminuric patients were moderately 
immunosuppressed (mean CD4 % of 16.8 ± 8%, mean viral load 8 ± 18 x 105 RNA copies/ml) 
and had WHO clinical stage 2 and 3 disease.  Absolute CD4 counts appear to correlate better 
with microalbuminuria than CD4 percentage as the mean CD4 absolute count in HIV positive 
patients with microalbuminuria (493 ± 330 x 106/l) was significantly lower than those without 
microalbuminuria (780 ± 702 x 106/l), p=0.03. 
 
 
Conclusion 
 
Microalbuminuria screening of HIV positive patients is a more sensitive screening test 
compared to standard urine dipsticks as it is present in patients with normal renal function 
who have no proteinuria.  This may allow for early identification of subclinical renal disease in 
patients with some evidence of immunosuppression; thus possibly preventing the 
deterioration of renal function and severity of HIV disease with early initiation of antiretroviral 
therapy. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 HIV-associated nephropathy (HIVAN) 
 
Since the first recorded case of Acquired Immune Deficiency Syndrome (AIDS) and the 
identification of Human Immunodeficiency Virus Type 1 (HIV) as the causative agent of AIDS, 
the HIV/AIDS epidemic has spread at an alarming rate throughout the world particularly in 
sub-Saharan Africa.  UNAIDS (2007) estimates about 2.1 million children worldwide are 
infected with HIV.  Although sub-Saharan Africa is home to just over 10% of the world’s 
population, nearly 90% of all children with HIV live in this region.1 
 
South Africa alone has almost a third of all new HIV infections and AIDS related deaths 
globally in 2007.  According to the Actuarial Society of South Africa the estimated HIV 
prevalence for children less than 18 years has almost doubled from 1.2% in 2000 to 2.1% in 
2006; with children less than 5 years of age being most affected.2 
 
Although HIV is a multisystem disease, the kidneys are commonly affected.  The spectrum of 
kidney disease in HIV is extensive and ranges from acute to chronic.  HIV associated 
nephropathy (HIVAN) is a chronic a disorder which was first described in adults and children 
with AIDS in New York and Miami in 1984.3  It is characterized by proteinuria and haematuria 
and the rapid development of renal insufficiency leading to end stage renal disease (ESRD).   
  2 
1.2 Prevalence 
 
The worldwide prevalence of childhood HIVAN is approximately 10-15%, especially in African 
American children.4,5  However, the true prevalence in African children is unknown due to a 
lack of surveillance and reporting of kidney disease in HIV positive children.   
 
 
1.3 Pathogenesis   
The pathogenesis of renal disease in HIV infection is not completely understood.  It is a 
complex inter-relationship between the HIV-1 which directly infects renal epithelial cells in a 
genetically susceptible host causing podocyte dysregulation and proliferation as well as 
mesangial hyperplasia.  Various cytokines (TNF α, IL-2, INF-γ), growth factors (PDGF, TGF-
β, FGF-2) and chemokines (IL-8, RANTES, monocyte chemo-attractant protein I) that are 
produced by HIV infected cells have been shown to play a role in the pathogenesis of  
HIVAN.6,7,8 
 
1.4 Clinical presentation 
 
HIVAN encompasses distinct syndromes; classic focal segmental glomerulosclerosis which is 
collapsing in nature (FSGS), immune complex mediated, mesangial hyperplasia and 
thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome (TTP/HUS).7 
 
Proteinuria seems to be the earliest and most consistent finding for the diagnosis of 
HIVAN.9,10  The degree of proteinuria is variable, from minimal to nephrotic range.  
  3 
The classical picture of nephrotic syndrome with peripheral oedema and 
hypercholesterolaemia is often absent but may be seen.7  Whether such clinical findings 
represents distinctive characteristics of the nephropathy or are simply indicative of overall 
health and nutritional status of the patients with advanced HIV disease is debatable.   
 
In immune complex disease hypertension and haematuria are common.  These patients have 
an indolent course and are less likely to progress to ESRD.  Mesangial hyperplasia may 
reflect an early stage of FSGS, however this there insufficient data to support this  
hypothesis.11  Patients with mesangial hyperplasia have proteinuria, are older and have an 
excellent prognosis as the rate of progression to renal failure is much slower. Patients with 
TTP/ HUS disease usually present with microangiopathic haemolytic anemia and mild to 
moderate renal insufficiency together with other features such as fever, thrombocytopenia 
and neurological changes.7 
 
 
1.5 HIVAN in children and adults 
 
In earlier reports of renal disease in HIV infected individuals, some noticeable differences 
existed between HIVAN in adults and children.  In adults, HIVAN tends to progress rapidly to 
ESRD and is associated with a higher mortality rate.  Whereas in children, progression to 
ESRD is slow, variable and highly dependent on the histological lesion.12    
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Children with focal glomerulosclerosis or segmental necrotizing glomerulonephritis tend to 
develop severe renal failure within 1 year of diagnosis and have a high mortality rate, usually 
from cause’s unrelated to renal insufficiency.12  In adults and children, outcome is dictated by 
progression of AIDS and is independent of the primary renal disease.6,13 
 
 
1.6 Diagnostic evaluation of HIV-associated nephropathy 
 
HIVAN may be the first manifestation of infection with HIV before the development of AIDS, 
although it predominantly occurs as a late stage complication.14  Most patients have advanced 
renal failure or AIDS defining illnesses at the time of diagnosis.  The length of time from 
detection of nephropathy to severe renal failure averaged 9 months with a range from 1 to 27 
months.12 
 
The kidneys are often large and echogenic on renal imaging studies.  The predictive value of 
renal ultrasound to prove or exclude the diagnosis of HIVAN has not been studied.  The only 
reliable test to establish the presence of HIVAN is a renal biopsy.  The more commoner 
glomerular abnormality is focal segmental glomerulosclerosis.  However, a spectrum of 
lesions may be present, and virtually all types of glomerular lesions have been described.15,16 
According to two South African studies, FSGS and immune mediated complex disease are 
common in children and adults.17,18    
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1.6.1 Microalbuminuria 
 
The normal rate of protein excretion in children is <4mg/ m2/hour or <100mg/m2/day 
throughout childhood in both boys and girls.19  Albumin excretion in spot urine in the range of 
20 to 200mg/l is referred to as microalbuminuria.20,21  At these levels, the standard dipsticks 
do not detect albumin in the urine and thus specific measurement of albumin using high 
albumin-sensitive techniques are required.   
 
Microalbuminuria, a type of glomerular proteinuria, is an early marker for the development of 
nephropathy and generalized endothelial dysfunction in diabetes.22  Similarly, in non 
diabetics, increased urinary albumin excretion may also indicate a renal glomerular 
disease.23,24   
 
Microalbuminuria may precede proteinuria and may be the only manifestation of HIV disease 
before the AIDS complex manifests.12  The prevalence of microalbuminuria in HIV 
seropositive adults varies.  It has been identified in 19.4% of HIV-infected adults and is 
inversely correlated with CD4 T-cell counts; however no prospective information is available 
regarding the progression to clinically significant renal disease in these patients.25  Han TM et 
al reported microalbuminuria in 36% of HIV-infected adults.9  In the Fat Redistribution and 
Metabolic Change in HIV Infection Study; microalbuminuria was present in 11% of HIV-
infected adults, but only in 2% of controls.26     
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1.7 Aims of the study 
 
In view of the paucity of data on the prevalence and clinical significance of microalbuminuria 
in HIV-seropositive children; a study was undertaken to assess microalbuminuria in relation to 
the clinical presentation of HIV/AIDS. Microalbuminuria is an independent risk factor for the 
development of chronic kidney disease and loss of glomerular filtration.22  Adult studies have 
shown that microalbuminuria is an early manifestation of HIVAN.9,12  Thus, the screening for 
urinary microalbumin may allow for early identification of renal involvement in patients with 
HIV/AIDS infection. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 Ethics clearance 
 
Approval was obtained from the Ethics Committee of the University of Witwatersrand.  
Clearance no: M050808 
 
 
2.2 Study sample 
 
A prospective, single centre trial was undertaken at Chris Hani Baragwanath Hospital (the 
major tertiary referral facility that serves the people of Soweto and surrounding areas of 
southern Gauteng), Department of Paediatrics, South Africa from March 2006 to December 
2007.  Patients were recruited aged 6 months to 16 years that were attending the HIV 
outpatient clinic (Harriet Shezi) and in patients from our general paediatric wards.  
 
The HIV status of patients was determined by enzyme linked immuno-absorbent assay 
(ELISA) or polymerase chain reaction (PCR).  The patients were divided into HIV infected or 
HIV uninfected groups.   
  8 
All HIV positive patients were on Trimethoprim-sulphamethoxazole prophylaxis for the 
prevention of Pneumocystis jiroveci. The study sample comprised 110 HIV seropositive and 
70 HIV seronegative patients. 
 
Exclusion criteria were as follows: 
• HIV positive patients on antiretroviral therapy 
• HIV positive patients on anti-tuberculosis treatment 
• Known chronic kidney disease (NKF KDOQI Clinical Practice guidelines for CKD in 
Children and Adolescents27) 
• Hypertension (blood pressure tables for adolescents and children, 
infants 28) 
• Fever 
• Acute illness  
• Urinary tract infection. 
 
Standard urine dipstick testing was performed using MAKROmed strips (Makromed 
Manufacturing, Judith’s Paarl, Johannesburg, South Africa) in all patients.  Patients with 
features of urinary tract infections and glycosuria were excluded.  A urine dipstick reading ≤ 
20 mg/dl (negative and trace) of protein was considered negative proteinuria and > 20mg/dl 
(≥ 1+) was labelled proteinuria.27   
 
The presence of microalbuminuria was assessed by Micral-Test strips (Roche Diagnostics, 
Laval, Québec, Canada) as per the manufacturer’s instructions.  A single morning urine 
specimen in all patients was collected.   
  9 
This is a simple, convenient and a reliable estimate of quantitative microalbumin excretion 
and it correlates well with the 24 hour urine collection.29  Urine excretion of 20-200mg/l was 
defined as microalbuminuria.30  Thus patients were categorized into negative (<20mg/l) and 
positive (≥ 20mg/l) microalbuminuria.  Confounding factors such as fever, exercise, acute 
illness, urinary tract infection, hypertension and diabetes mellitus and anti-tuberculosis 
treatment were excluded.  Glomerular filtration (GFR) was calculated using the Schwartz 
formula and expressed as milliliters/minute/1.73 metre squared (ml/min/1.73m2)31.    
 
 
2.3 Data collection 
 
Informed consent was obtained from the parent and assent from patients over  
7 years of age. Demographics (age, sex, and race), nutritional status, comorbid conditions 
(diabetes mellitus, hypertension, and tuberculosis), current clinical presentation and 
laboratory measurements (full blood count, serum creatinine, serum total protein, serum 
albumin, CD4 count, and viral load) were extracted from patients’ medical records.  All data 
was captured and edited on Microsoft® Access 2003. 
 
 
2.4 Statistical analysis 
 
Statistical analysis was performed using Statistica 7.1 (StatSoft, Inc. 1984-2006, USA).  
Descriptive statistics using means, medians, standard deviation and confidence intervals 
were performed on all variables where appropriate.  
  10 
Patients with and without microalbuminuria in both the HIV positive and negative groups were 
compared using the student’s t test (dependent or independent samples) for continuous 
variables, and the Fisher’s Exact or Chi-square tests were used for categorical data. P values 
< 0.05 were regarded as significant.   
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CHAPTER 3 
 
 
RESULTS 
 
 
A total of 180 patients were enrolled into the study; of which 110 were HIV positive and 70 
HIV negative from both an inpatient and an outpatient ambulatory setting.   
 
 
3.1 Age and racial distribution 
 
There were 100 (56%) males and 80 (44%) females, with a ratio of 1.3:1.  The majority of 
patients were black 177 (98%), reflecting the population of the catchment area, while 3 (2%) 
were of mixed races.  The overall mean age at presentation was 4 years; ranging from 6 
months to 16.5 years, see table 1.  Majority of the HIV seropositive patients were older than 5 
years with a mean of 5.8 ± 3.2 years at presentation but the HIV seronegative patients were 
younger than 5 years of age with a mean of 2 ± 2.1 years, p=0.0002.  
 
 
 
 
 
 
 
  12 
Table 1   Age at presentation  
Age 
(months) HIV positive n=110 HIV negative n=70 P value 
 No. (%) No. (%) 
 
6 to 12 6 (5.5) 22 (31) 0.73 
13 to 60 36 (33) 42 (60) 0.0006 
60 to 120 59 (54) 5 (7) 0.007 
> 120 8 (7) 1 (1) 0.4 
 
 
3.2 Nutritional status 
 
Figure 1 summarises the nutritional status (CDC 2000 growth charts 32) of HIV positive and 
HIV negative patients.  26 (24%) HIV positive patients and 1(1.4%) HIV negative patient with 
recumbent length or stature greater than 121cm were not defined according to the CDC 
weight for stature growth charts.  The mean nutritional assessment of the entire population 
was optimal, even though significant differences were noted in length or height and weight for 
length or height in both groups.  However, this is due to patients being either adequately 
nourished or extremely malnourished, but generally the HIV negative patients were more 
malnourished as expected for length or height (p=0.005) and weight for length or height 
(p=0.004). 
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Figure 1   Nutritional status of HIV positive and HIV negative patients 
 
 
3.3 Clinical features  
 
The primary clinical features at the time of screening for both the HIV positive and negative 
patients are summarised in table 2.  Lower respiratory tract infection was the commonest 
presentation in both groups.   
  
 
 
 
 
 
Weight Length or Height 
Weight for Length 
or Height 
p=0.14 p=0.005 p=0.004 
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Table 2    Clinical characteristics at presentation 
HIV positive HIV negative 
  
n=110 
No. (%) 
 
n=70 
No. (%) 
 
Upper respiratory tract infection 18 (16.4) 5   (7.1) 
Lower respiratory tract infection 28 (25.5) 20 (28.6) 
Cardiovascular disease - 3   (4.3) 
TB pleural effusion 1   (0.9) - 
Gastroenteritis 5   (4.5) 21 (30) 
Central nervous system disease 2   (1.8) 10 (17.3) 
Other 10 (9.1) 18 (28.7) 
 
 
3.4 Microalbuminuria 
 
Microalbuminuria was present in 28 (15%) patients.  3 patients with indeterminate 
microalbuminuria due to tuberculosis treatment were excluded.  An overview of patients 
tested for microalbuminuria is summarized in figure 2.  Of the 28 patients with 
microalbuminuria, 27 (25%) were HIV positive and 1 (1%) HIV negative, p=0.00003. 
Thus indicating probable early renal disease in the HIV positive group. 
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Figure 2   Overview of patients tested for microalbuminuria 
* 3 patients (2 HIV positive and 1 HIV negative) with indeterminate microalbuminuria due to tuberculosis treatment 
were excluded 
 
 
3.4.1  HIV positive group (n=27) 
 
3.4.1.1 Age at presentation 
 
The mean age at presentation of HIV positive patients with microalbuminuria was 6 ± 3.2 
years (1-11.3 years) and those patients without microalbuminuria was  
6 ± 3.3 years (0.6-16.6 years), p=0.6.   
 
3.4.1.2 Nutritional status 
 
The nutritional status of patients with and without microalbuminuria was optimal with no 
statistical differences, see figure 3. 
n=180  
HIV positive 
110 (61%) 
HIV negative 
70 (39%) 
 
Microalbuminuria Microalbuminuria 
 
Negative  
81 (74%)* 
Positive 
27 (25%) 
Negative 
68 (97%)* 
 
Positive 
1 (1%) 
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Figure 3   Nutritional status of patients positive and negative microalbuminuria 
 
 
3.4.1.3 Clinical presentation  
 
Of the 27 patients that presented with microalbuminuria, 19 (70%) were symptomatic and 9 
(30%) were asymptomatic.  The clinical characteristics of HIV positive patients with 
microalbuminuria were categorised according to the revised WHO clinical staging of 
HIV/AIDS 33, and are represented in table 3.   
 
 
 
 
 
 
p=0.2 p=0.3 p=1 
Length or Height Weight 
Weight for Length 
or Height 
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Table 3   Clinical characteristics of HIV positive patients tested for microalbuminuria 
WHO Staging 
  1 2 3 4 
WHO Staging Condition No. (%) No. (%) No. (%) No. (%) 
Asymptomatic 
 
1 
(4) 
      
Persistent generalized 
lymphadenopathy 
13 
(16) 
2 
(7)       
Hepatosplenomegaly 
  
5 
(6) 
6 
(22)     
Papular pruritic eruptions 
   
1 
(4) 
    
Parotidmegaly 
  
3 
(4) 
1 
(4) 
    
Herpes zoster 
  
2 
(2) 
     
Extensive molluscum 
  
1 
(1) 
     
Recurrent or chronic URTI 
  
6 
(7) 
1 
(4)     
Moderate unexplained malnutrition 
    
10 
(12)    
Pulmonary TB 
    
20 
(25) 
8 
(30)   
Severe recurrent LRTI 
    
4 
(5)    
Chronic HIV-associated lung disease 
including  bronchiectasis 
     
1 
(4)   
Lymphoid interstitial pneumonia 
    
10 
(12) 
3 
(11) 
  
Severe unexplained malnutrition 
      
7 
(9) 
1 
(4) 
Extrapulmonary TB 
      
2 
(2) 
1 
(4) 
HIV encephalopathy 
      
4 
(5) 
2 
(7) 
Disseminated non-tuberculous 
mycobacterium infection 
       
2 
(7) 
Some patients have >1 clinical feature from the same stage, Shaded areas denotes negative microalbuminuria 
and unshaded areas denotes positive microalbuminuria 
 
  18 
Tuberculosis and lymphoid interstitial pneumonia (LIP) was common among HIV positive 
patients. However, 40% of patients with LIP had associated tuberculosis.  This association 
was present only in patients without microalbuminuria.   HIV positive patients with 
microalbuminuria had predominantly stage 2 (30%) and 3 (37%) disease clinically,  
see figure 4. 
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Figure 4   WHO staging characteristics of HIV positive patients with negative and positive 
microalbuminuria 
 
 
 
 
 
 
p=0.4 
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3.4.1.4 Laboratory parameters 
 
The mean CD4 percentage of HIV seropositive patients with microalbuminuria was  
16.8 ± 8 % (1.4-29%) compared to those without microalbuminuria was 20 ± 8 % (1.4-41%), 
p=0.4.  This correlated to a CDC immunological category 2 (moderate 
 immunosuppression).34  However, statistical significance was only noted in patients with no 
evidence of immunosuppression (category 1), see figure 5.     
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Figure 5   CDC Immunological categories (based on CD4 %) of HIV positive patients with 
negative and positive microalbuminuria 
(CDC immunologic category 1= no, 2= moderate and 3= severe immunosuppression) 34 
 
 
 
p=0.2 p=0.02 p=0.9 
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The mean CD4 absolute count in HIV positive patients with microalbuminuria (493 ± 330 x 
106/l) was significantly lower than those without microalbuminuria (780 ± 702 x 106/l), p=0.03; 
especially in immunologic categories 1 and 2, see figure 6.  Thus the absolute count maybe a 
more important factor than percentage CD4 count as in adult HIV disease.9,25,26     
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Figure 6   CDC Immunological categories (based on CD4 absolute count) of HIV positive 
patients with negative and positive microalbuminuria 
 
 
Therefore, the majority of microalbuminuric patients have moderate to no 
immunosuppression (CDC immunologic categories 1 and 2) on the basis of CD4 absolute 
counts and percentages indicating some degrees of preservation of immune function, see 
figure 7.   
 
p=0.8 p=0.03 p=0.0003 
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Figure 7   Comparison of CD4 absolute count and percentage (CDC Immunological 
categories) of HIV positive patients with negative and positive microalbuminuria 
 
 
The mean viral load for HIV seropositive patients with and without microalbuminuria was  
8 ± 18 x 105RNA copies/ml (0.006 to 91 x 105RNA copies/ml) and 3 ± 7 x 105RNA copies/ml 
(0.003 to 30 x 105RNA copies/ml) respectively (p=0.1).  The majority of patients with and 
without microalbuminuria have viral loads <100 000 RNA copies/ml, see table 4.  The mean 
globulin concentration in patients with and without microalbuminuria was 68g/l ± 16 and 53g/l 
± 14 respectively (p=0.1).  Thus the viral load and high globulins are probably factors not 
associated with microalbuminuria.   
 
 
 
 
CD4 absolute count 
(p=0.8) 
CD4 percentage 
(p=0.8) 
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Table 4   Viral load in patients with negative and positive microalbuminuria 35   
Microalbuminuria 
Viral load  
 
Negative 
No. (%) 
Positive 
No. (%) 
<100 000 53 (50) 16 (15) 
≥100 000 25 (24) 11 (10) 
P value 0.5 
 
 
In patients with HIV, proteinuria was present in 8 (7%) patients and none in 100 (93%) 
patients.  In the absence of the proteinuria, microalbuminuria was present in 21 (19%) 
patients.  Of the remaining 8 patients with proteinuria, 6 (6%) had microalbuminuria and no 
haematuria, see table 5.  Thus microalbuminuria is more sensitive than standard urine 
dipstick for proteinuria in screening for renal disease in the presence of HIV, p=0.03. 
 
 
Table 5   Urine dipstick of patients with negative and positive microalbuminuria  
Microalbuminuria 
Negative  Positive 
  
n=81 
No. (%) 
n=27 
No. (%) 
≤ 20mg/dl 79 (73) 21 (19) Proteinuria (p=0.03) 
 > 20mg/dl 2 (2) 6 (6) 
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In assessing the renal function of patients with microalbuminuria, the mean creatinine was  
37 ± 7 (11-70), p=0.08 and the estimated GFR 155 ± 43 ml/min/1.73m2 ranging from normal 
to hyperfiltration (80-241 ml/min/1.73m2), p=0.7.  This was similar to patients without 
microalbuminuria (mean creatinine 35 ± 11 [21-48µmol/l] and estimated GFR 154 ± 62 
ml/min/1.73m2 [71-440 ml/min/1.73m2]).  Hyperfiltration was only noted in malnourished 
patients, see table 6.  
 
 
Table 6   Calculated glomerular filtration rate (Schwartz GJ et al31) in relation to nutritional 
status  
GFR (ml/min/1.73m2) 
Mean ± SD Range  Nutritional 
status neg MA pos MA neg MA pos MA 
  
P value 
 
Normal  128*  102* 117-216 84-154 0.3 
Moderate 
malnutrition 0 0 0 0 0 
Severe 
malnutrition 141 ± 36 142 ± 40 71-216 80-223 0 
*Median GFR, SD=standard deviation 
Classification of malnutrition based on the WHO Technical Report Series36  
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CHAPTER 4 
 
DISCUSSION 
 
 
Proteinuria is a common feature of HIV infection in children.  In our paediatric outpatient HIV 
unit, all HIV positive patients are screened for renal disease at every follow-up visit by 
standard urine dipsticks.  In the absence of underlying urinary tract infections, patients with 
persistent proteinuria or hematuria, have further evaluation of renal function by measuring the 
urea, creatinine and electrolytes.  This is followed by measuring urine protein to creatinine 
ratio and by ultrasound imaging to assess kidney size, as large echogenic kidneys are a 
feature of HIVAN.     
 
The most salient observation in our study was the association between microalbuminuria and 
the absence of proteinuria.  When screening for renal disease in HIV using standard urine 
dipsticks, patients with subclinical renal disease will not be detected.  Urine dipsticks are poor 
diagnostic tools for assessing proteinuria as they lack sensitivity and have a low negative 
predictive value. 37  Although HIVAN can present in asymptomatic HIV infected patients, 
massive proteinuria and renal insufficiency are late manifestations as evidenced by low 
number of CD4 cells.38  With normal renal function and no proteinuria, microalbuminuria was 
present in our patients with moderate to no immunosuppression.  
 
 
  25 
Thus suggesting that microalbumin assessment of urine is a sensitive screening test 
compared to standard urine dipsticks however, the specificity of microalbumin testing for 
HIVAN needs to be evaluated in further paediatric studies in patients with renal biopsy proven 
HIVAN and serial measurements of microalbuminuria.   
 
HIVAN is possible in patients without overt nephrotic syndrome and even in patients who only 
have microalbuminuria.  Han TM et al measured persistent microalbuminuria in 7(8%) of 90 
patients tested. 9  Interestingly of the 7 patients, 6 patients were biopsy proven HIVAN with 
normal renal function and the mean urine protein excretion was 0.14g/24hr, thus indicating 
that microalbuminuria is an early indicator of subclinical renal disease in HIV. Similarly, 
microalbuminuria has been evaluated by many investigators to diagnose subclinical renal 
involvement in other systemic diseases, eg. systemic lupus erythematosus and diabetes 
mellitus with renal involvement. 
 
Valente de AR et al performed renal biopsies in 30 patients with systemic lupus 
erythematosus with microalbuminuria but no clinical signs of renal involvement.  Fifteen 
(50%) of cases had mesangial glomerulonephritis (MGN) type 2b, 12 (40%) had MGN type 
2a and 3 (10%) showed no changes on light microscopy or immunofluorescence.39  Similarly, 
a significant number of microalbuminuric diabetic patients had diabetic nephropathy and no 
overt proteinuria.40   
 
The presence of microalbuminuria in the face of proteinuria suggests mainly the excretion of 
albumin. This may be due to the pathophysiological mechanism of increased glomerular 
capillary wall permeability from charge selectivity 41 in HIVAN.  
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When profiling for proteinuria in paediatric patients with any chronic disease, the percentage 
of albuminuria is greatest in those with glomerular disease as compared to those with tubular 
dysfunction.37   Over 80% HIV positive patients with subclinical renal disease have glomerular 
permeability defects or tubular dysfunction.42   
 
The prevalence of microalbuminuria; based on a single morning urine sample in our HIV 
infected children prior to commencing antiretroviral therapy, was 25%.  This association 
between HIV and microalbuminuria has been observed in adults, with prevalence rates 
varying between 8.7% to 30%.9,25,26,43  However, to date no paediatric studies have been 
undertaken to assess this association. 
 
In our study, HIV infected children with microalbuminuria were older than 5 years of age with 
clinical stage 2 and 3 disease.   Kimmel PL et al have showed that microalbuminuria is not 
related to the staging of HIV infection.43 
 
In 2 published adult studies, CD4 count >200 cells/mm3 have been associated with 
microalbuminuria.9,25 Similarly in our study majority of patients had evidence of  moderate 
immunosuppression with some preservation of immune function.  This is in contrast to the 
findings by Szczech L et al, where microalbuminuric patients had mean CD4 counts 
<200cells/ml.26   
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The CD4 cell counts in children are much higher than adults especially in early childhood.44  
In the first few months after birth the CD4 counts may be above 200 cells/mm3 (compared to 
500-1200 cells/mm3 in uninfected adults) and it declines as the child gets older; reaching adult 
levels in late childhood (by age 6 years). In contrast, the CD4 count and percentage are 
stable throughout adulthood.  But absolute counts correlate better with microalbuminuria as 
shown in our study.  However, the use of CD4 percentage over absolute counts in children is 
recommended to guide and monitor HIV treatment as it is relatively stable in young children.   
 
When comparing the clinical characteristics of patients with microalbuminuria, there was no 
significant difference in age, gender, nutritional status, clinical presentation, CD4 percentage, 
viral load or renal function, this is similar to findings by Baekken M et al. 45  Although LIP and 
tuberculosis are commonly associated with HIV, according to Kala U et al,17  there is a good 
correlation between LIP and immune complex mediated HIVAN. 
 
In other adult studies risk factors for microalbuminuria varied according to the study design. 
Urinary microalbumin levels correlated with CD4 cell counts, white blood cell counts and 
clinical AIDS in a study by Luke DR et al. 25  Szeczech LA et al demonstrated that CD4 
lymphocyte counts <200 cells/mm3, viral load together with hypertension and insulin 
resistance predicted the severity of microalbuminuria in HIV. 26  Larger studies with serial 
microalbumin measurements and correlation with renal histology are required to differentiate 
better the combination of the various factors causing microalbuminuria. 
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Limitations 
 
It is important to note the limitations of this study.   
• The true prevalence of microalbuminuria in our study may be an overestimation.  Single 
urine samples were taken, thus the change in microalbuminuria could not be assessed.  
Although albumin excretion is variable on a daily basis there is increasing evidence that 
persistent proteinuria is a marker of both renal disease and progressive renal injury.19  
In diabetes, 40-50% of initial microalbuminuria progress to persistent, 30-60% show 
intermittent microalbuminuria, while 20% never develop microalbuminuria.  The 
prognostic value of a single sample with microalbuminuria in diabetes is of limited value.  
The positive predictive and negative predictive values are 76% and 99.5% respectively.46    
Abitbol CL et al also noted that the degree of proteinuria correlated with loss of renal 
function and progression to ESRD, in chronic kidney disease of any cause in children.37 
The above may apply to HIV, however further surveillance and studies are required. 
 
• Although the relationship between HIVAN and microalbuminuria could not be evaluated 
by renal biopsy in this population, adult studies have shown that HIVAN is associated with 
microalbuminuria.  In a study by Han TM et al, in 7 patients with persistent 
microalbuminuria, 6 had HIVAN and 1 interstitial nephritis.9   
 
In another study, 107 HIV patients that underwent renal biopsy, 52 (49%) presented with 
non nephrotic proteinuria and 55 (51%) nephrotic range proteinuria.  Of the patients with 
non nephrotic proteinuria, HIVAN was confirmed in 11 (21%) patients while 41 (79%) 
showed non HIV associated nephropathy.47   
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• The evaluation of renal function by calculated GFR may not reflect true renal function; 
especially in children with low muscle mass because the constant k tends to be lower in 
this subset of patients.  In malnourished children methods for measuring GFR are 
required as there are no studies that have validated approaches using plasma creatinine 
and anthropometric measurement of muscle mass.31  
 
• There were more HIV positive patients than negative, thus selection bias cannot be 
completely excluded.   
 
 
Strengths 
This is the first prospective study to assess microalbuminuria in black South African HIV 
positive children as a screening test for early renal involvement. 
 
 
Clinical relevance and recommendations 
 
With the increasing prevalence of HIV and HIV related complications, the HIV Medicine 
Association of America have recommended screening for kidney disease in HIV infected 
individuals. 48  Just as the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF KDQI) guidelines for diabetes,22  uses microalbuminuria to screen for early 
renal disease, so to should this screening test be implemented in HIV.  Also, spot albuminuria 
should be used in screening for renal disease in paediatrics as significant proteinuria can be 
missed in older children.37 
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CHAPTER 5 
 
CONCLUSION 
 
 
Microalbuminuria is prevalent in HIV seropositive children especially those over 5 years of 
age without clinical evidence of any AIDS defining illnesses.   Majority of microalbuminuric 
patients have moderate to no evidence of immunosuppression.  Absolute CD4 counts appear 
to better correlate with microalbuminuria than CD4 percentage.  In the absence of proteinuria; 
microalbuminuria does indicate subclinical renal disease; however, it is a not valid diagnostic 
test for HIVAN as yet.  Renal biopsy still remains the gold standard for diagnosing HIVAN.  A 
renal biopsy may be indicated in those patients presenting with persistent microalbuminuria 
with normal renal function.  Early screening for microalbuminuria in HIV positive patients 
when immune function is still preserved may possibly prevent both progression of renal 
disease and underlying HIV with early initiation of antiretroviral therapy. 
   
Future studies that can arise from this study: 
• To assess the association between microalbuminuria and biopsy proven nephropathy in 
HIV positive children.          
• Repeat sampling of microalbuminuria in HIV infected children to assess the true 
prevalence and/ or persistence of microalbuminuria. 
• To assess calculated GFR in malnourished HIV positive and negative children by 
radioisotopes and to determine a possible correction factor in these patients that can be 
used in the calculation of GFR utilizing the Schwartz formula. 
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